2012
DOI: 10.1016/j.mce.2011.07.035
|View full text |Cite
|
Sign up to set email alerts
|

Structural determinants of ligand binding to the mineralocorticoid receptor

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
29
0

Year Published

2013
2013
2023
2023

Publication Types

Select...
4
3
1

Relationship

0
8

Authors

Journals

citations
Cited by 39 publications
(29 citation statements)
references
References 65 publications
0
29
0
Order By: Relevance
“…Further, since the interaction between the N-and C-terminal domains is ligand-specific, MR undergoes ligand-specific conformational changes. This conformational change might affect the interaction with co-regulator proteins which would induce the ligand-specificity (Pippal et al, 2011;Huyet et al, 2012;Fuller et al, 2012).…”
Section: Discussionmentioning
confidence: 99%
“…Further, since the interaction between the N-and C-terminal domains is ligand-specific, MR undergoes ligand-specific conformational changes. This conformational change might affect the interaction with co-regulator proteins which would induce the ligand-specificity (Pippal et al, 2011;Huyet et al, 2012;Fuller et al, 2012).…”
Section: Discussionmentioning
confidence: 99%
“…For this review we have selected eight genes that when mutated or deleted cause the most severe phenotypes in humans (FIGURE 6B), indicating that they are coding for proteins that are limiting factors in the aldosterone signaling pathway and critical in establishing vectorial reabsorption of sodium in ASDN. These genes code for 1) the MR (156,158,235); 2) 11␤-HSD2 (48,240), which protects the MR from illicit occupancy by glucocorticoids (cortisol or corticosterone); 3) ENaC ␣-, ␤-, or ␥-subunit (174,278); and 4) Na ϩ -K ϩ -ATPase ␣-, ␤-, and ␥-subunit (118,119). Mutations of the regulatory subunit (␥ or FXYD2) are compatible with survival (115) unlike lossof-function mutations on ␣␤, which have not been observed in humans because they are likely to be embryonic lethal according to gene inactivation in transgenic mouse models (20).…”
Section: Genetic Evidence For the Limiting Stepsmentioning
confidence: 99%
“…Research from several laboratories (32,33,36,121,158) provided insights into the structural basis for changes in the response of the MR and GR to corticosteroids. In particular, three sites in vertebrate CR, MR, and GR provide clues to the evolution of the MR and GR that led to their divergence in their specificity for corticosteroids.…”
Section: Structural and Sequence Analysis Of Three Key Sites That Infmentioning
confidence: 99%
“…An injectable preparation (potassium canrenoate) is more widely available. Of note, progesterone is a natural MRA (Huyet et al, 2012). Eplerenone (9-11a-epoxymexrenone), a second generation MRA, was developed by Ciba-Geigy (Basel, Switzerland) and launched by Pfizer (New York, NY) in 2002 for the treatment of hypertension and heart failure MR antagonism for:…”
Section: A Steroidal Compoundsmentioning
confidence: 99%
“…In the kidney, this should induce permanent maximal sodium retention, independent of plasma aldosterone levels. The main mechanism ensuring in vivo mineralocorticoid selectivity involves coexpression of MR and the enzyme 11b hydroxysteroid dehydrogenase type 2 (11HSD2), that metabolizes circulating glucocorticoid hormones (cortisol in humans, corticosterone in rodents) into inactive 11-dehydro-derivatives (cortisone, 11-dehydrocorticosterone) with very low affinity for the MR (Farman and Rafestin-Oblin, 2001;Huyet et al, 2012;Odermatt and Kratschmar, 2012). Other mechanisms are important for mineralocorticoid selectivity (i.e., the events that explain the higher efficacy of MR-aldosterone versus MR-glucocorticoid complexes) (Farman and Rafestin-Oblin, 2001;Viengchareun et al, 2007;Fuller et al, 2012).…”
Section: Introductionmentioning
confidence: 99%